MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: Discovery and early strategies for lead optimization

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 23, 2003, Pages 4201-4204

  Nakayama, Kiyoshi ^a   Ishida, Yohei ^a   Ohtsuka, Masami ^a   Kawato, Haruko ^a   Yoshida, Ken Ichi ^a   Yokomizo, Yoshihiro ^a   Hosono, Shigeru ^a   Ohta, Toshiharu ^a   Hoshino, Kazuki ^a   Ishida, Hiroko ^a   Yoshida, Kumi ^a   Renau, Thomas E ^b   Léger, Roger ^b   Zhang, Jason Z ^b   Lee, Ving J ^b   Watkins, William J ^b  

^a DAIICHI SANKYO CO   (Japan)

^b Essential Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; LEVOFLOXACIN; MEMBRANE EFFLUX AB OPRM PROTEIN; MEMBRANE EFFLUX AB OPRM PROTEIN INHIBITOR; MEMBRANE PROTEIN; MEROPENEM; PIPERACILLIN; PLASMA PROTEIN; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG SYNTHESIS; MOUSE; NODULATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STRUCTURE ACTIVITY RELATION;

ANIMALIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0242569169     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.07.024     Document Type: Article

References (35)

1. Gold H.S., Moellering R.C. Jr. New Engl. J. Med. 335:1996;1445.
2. Chu D.T.W., Plattner J.J. J. Med. Chem. 39:1996;3853.
3. Domagala, J. M.; Sanchez, J. P. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic: New York, 1997; p 111.
4. Perl T.M. Am. J. Med. 106:1999;26. S.
5. Chopra I. Curr. Opin. Microbiol. 1:1998;495.
6. Lawrence L.E., Barrett J.F. Exp. Opin. Invest. Drugs. 7:1998;199.
7. Marshall N.J., Piddock L.J. Microbiologia. 13:1997;285.
8. Nikaido H. Clin. Infect. Dis. 27:1998;S32.
9. Lee V.J., Lomovskaya O. CLEAR. 1:1998;39.
10. Levy S.B. Antimicrob. Agents Chemother. 36:1992;695.
11. Li X.Z., Livermore D.M., Nikaido H. Antimicrob. Agents Chemother. 38:1994;1732.
12. Li X.Z., Ma D., Livermore D.M., Nikaido H. Antimicrob. Agents Chemother. 38:1994;1742.
13. Hancock R.E. Clin. Infect. Dis. 27(Suppl. 1):1998;S93.
14. Poole K., Krebes K., McNally C., Neshat S. J. Bacteriol. 175:1993;7363.
15. Poole K., Gotoh N., Tsujimoto H., Zhao Q., Wada A., Yamasaki T., Neshat S., Yamagishi J., Li X.Z. Nishino, Mol. Microbiol. 21:1996;713.
16. Koehler T., Michea-Hamzehpour M., Henze U., Gotoh N., Curty L.K., Pechere J.C. Mol. Microbiol. 23:1997;345.
17. Mine T., Morita Y., Kataoka A., Mizushima T., Tsuchiya T. Antimicrob. Agents Chemother. 43:1999;415.
18. Renau T.E., Léger R., Flamme E.M., Sangalang J., She M.W., Yen R., Gannon C.L., Grith D., Chamberland S., Lomovskaya O., Hecker S.J., Lee V.J., Ohta T., Nakayama K. J. Med. Chem. 42:1999;4928.
19. Renau T.E., Léger R., Flamme E.M., She M.W., Gannon C.L., Mathias K.M., Lomovskaya O., Chamberland S., Lee V.J., Ohta T., Nakayama K., Ishiada Y. Bioorg. Med. Chem. Lett. 11:2001;663.
20. Renau T.E., Léger R., Yen R., She M.W., Flamme E.M., Sangalang J., Gannon C.L., Chamberland S., Lomovskaya O., Lee V. J. Bioorg. Med. Chem. Lett. 12:2002;763.
21. Lomovskaya O., Warren M.S., Lee A., Galazzo J., Fronko R., Lee M., Blais J., Cho D., Chamberland S., Renau T., Léger R., Hecker S., Watkins W., Hoshino K., Ishida H., Lee V. Antimicrob. Agents Chemother. 45:2001;105.
22. Lomovskaya O., Lee A., Hoshino K., Ishida H., Mistry A., Warren M.S., Boyer E., Chamberland S., Lee V.J. Antimicrob. Agents Chemother. 43:1999;1340.
23. Hoshino, K.; Ishida, H.; Okumura, R.; Nakayama, K.; Hayakawa, I; Sato, K. In 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 2002; Abstract F-728. Further details of the microbiological and biochemical characterization and potential clinical utility of MexAB-OprM specific inhibitors will be reported elsewhere in due course.
24. Maehr H., Yang R. Tetrahedron Lett. 37:1996;5445.
25. Hayashi, Y; Oguri, T.; Shinoda, M.; Tsutsui, M.; Takahashi, K.; Miida, H.; Eur. Pat. 0219436.
26. Francis, G. F.; Raymond, J. V.; Joseph W. Z.; Eur. Pat. 0355353.
27. Tamura Y., Sasho M., Akai S., Kishimoto H., Sekihachi J., Kita Y. Chem. Pharm. Bull. 35:1987;1405.
28. Tamura Y., Sasho M., Akai S., Kishimoto H., Sekihachi J., Kita Y. Tetrahedron Lett. 27:1986;195.
29. Zahra J., Hennig L., Findeisen M., Welzel P., Mueller D., Sheldrick W.S. Tetrahedron Lett. 42:2001;2969.
30. Deady L.W., Rodemann T. J. Heterocycl. Chem. 38:2001;1185.
31. Ihle N.C., Krause A.E. J. Org. Chem. 61:1996;4810.
32. 6 CFU/mL. MICs were determined after 18-h incubation at 37°C. For AZT, MICs were determined by visual observation of growth; for LVFX, the determination was made at 70% inhibition of growth, as measured by OD 595 nm.
33. Frostell-Karlsson A., Remaeus A., Roos H., Andersson K., Borg P., Hamalainen M., Karlsson R. J. Med. Chem. 43:2000;1986.
34. Colmenarejo G., Alvarez-Pedraglio A., Lavandera J.-L. J. Med. Chem. 44:2001;4370.
35. The effects of the addition of 0.125% human serum albumin upon activity in vitro were comparable to those with 10% horse serum for key compounds.